Publications by authors named "W R Strohl"
Since the SARS-CoV-2 Omicron virus has gained dominance worldwide, its continual evolution with unpredictable mutations and patterns has revoked all authorized immunotherapeutics. Rapid viral evolution has also necessitated several rounds of vaccine updates in order to provide adequate immune protection. It remains imperative to understand how Omicron evolves into different subvariants and causes immune escape as this could help reevaluate the current intervention strategies mostly implemented in the clinics as emergency measures to counter the pandemic and, importantly, develop new solutions.
View Article and Find Full Text PDFArticle Synopsis
- In 2023, the FDA approved 55 new molecular entities, including 12 therapeutic antibodies, and 5 non-antibody protein drugs, making protein drugs 31% of total approvals.
- Of the 12 approved antibodies, 8 were standard IgG, 3 were bivalent bispecific, and 1 was a trivalent bispecific antibody, with no new antibody-drug conjugates or CAR-T therapies approved.
- Key targets for the approved antibodies included various receptors for conditions like cancer, Alzheimer's disease, and severe colitis, addressing specific orphan indications and other serious health issues.
An ACE2 decamer viral trap as a durable intervention solution for current and future SARS-CoV.
Emerg Microbes Infect
December 2023
Article Synopsis
- * A new antiviral strategy using an inhaled recombinant viral trap that combines multiple ACE2 proteins shows strong effectiveness against various SARS-CoV-2 variants and other coronaviruses.
- * This ACE2 decameric viral trap can be used both before and after infection, is stable for over twelve weeks at room temperature, and proves protective in animal studies, indicating promise for future pandemic responses.
Article Synopsis
- * Researchers developed a novel monoclonal antibody (mAb) called "mAbtyrin" that targets multiple bacterial processes, enhancing its effectiveness against S. aureus.
- * mAbtyrin showed improved protection in preclinical models, including better defense against infections and enhanced effectiveness when used with vancomycin, suggesting it could be a promising treatment for S. aureus-related diseases.
The COVID-19 pandemic is now approaching 2 years old, with more than 440 million people infected and nearly six million dead worldwide, making it the most significant pandemic since the 1918 influenza pandemic. The severity and significance of SARS-CoV-2 was recognized immediately upon discovery, leading to innumerable companies and institutes designing and generating vaccines and therapeutic antibodies literally as soon as recombinant SARS-CoV-2 spike protein sequence was available. Within months of the pandemic start, several antibodies had been generated, tested, and moved into clinical trials, including Eli Lilly's bamlanivimab and etesevimab, Regeneron's mixture of imdevimab and casirivimab, Vir's sotrovimab, Celltrion's regdanvimab, and Lilly's bebtelovimab.
View Article and Find Full Text PDF